Teixobactin has not yet been tested in humans, so its safety and effectiveness are not known. Studies in people will not begin for about two years, according to Kim Lewis, the senior author of the article and director of the Antimicrobial Discovery Center at Northeastern University in Boston. Those studies will take several years, so even if the drug passes all the required tests, it still will not be available for five or six years, he said during a telephone news conference on Tuesday. If it is approved, he said, it will probably have to be injected, not taken by mouth.
Teixobactin尚未接受过人体试验,因此它的安全性和有效性尚属未知。该文章的责任作者,美国东北大学抗微生物药物发现中心(Antimicrobial Discovery Center at Northeastern University,位于波士顿)主任基姆·刘易斯(Kim Lewis)称,要展开人体研究大概还需要两年左右。他还在上周二的电话资讯发布会上说,这些研究将花费数年时间,所以即使该药物通过了所有必需的测试,也还需要五六年的时间才能面世。如果能通过审批,他说,该药物很可能采用注射给药,而非口服。
Experts not involved with the research said the technique for isolating the drug had great potential. They also said teixobactin looked promising, but expressed caution because it has not yet been tested in humans.
几位未参与该研究的专家表示,这种用于分离药物的技术具有巨大的潜力。他们还说,teixobactin看起来前途无量,但因为毕竟它尚未经过人体试验,他们也都表现出了谨慎的态度。
【关于抗生素的一条好消息】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15